Jedd D. Wolchok - Concepedia

Author

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Akhil Santhosh, Christine A. Iacobuzio-Donahue, Christine Iacobuzio-Donahue, Hyewon Ryu, J D Wolchok, J WOLCHOK, J Wolchok, J. D. Wolchok, J. Wolchok, J.-D. Wolchok

1.4K

Publications

202.9K

Citations

172

H-Index

202

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Dana-Farber Cancer Institute Bristol-Myers Squibb (United States)Swim Across America

About

Jedd D. Wolchok is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	95	242	60.3K
2	Health Sciences	26	38	12.4K
3	Engineering	6	6	1K
4	Natural Sciences	2	2	42
5	Law	1	1	1.8K

Jedd D. Wolchok

438

Publications

167.3K

Citations

152

H-Index

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Science	2015	7.8K
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2017	5.3K
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert, L. Thomas, Igor Bondarenko, New England Journal of Medicine	2011	4.4K
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Alexandra Snyder, Vladimir Makarov, Taha Merghoub, New England Journal of Medicine	2014	4.3K
Tumor mutational load predicts survival after immunotherapy across multiple cancer types Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Nature Genetics Cancer ImmunosurveillanceTumor HeterogeneityMedicineImmunologyPathology	2019	4.2K
Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, New England Journal of Medicine	2013	4.2K
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET Héctor Peinado, Maša Alečković, Simon Lavotshkin, Nature Medicine ExosomesMedicineMelanomaBiological MicroenvironmentsStem Cell Research	2012	3.6K
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2019	3.6K

Page 1